Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

Nov. 5, 2020

Phase III results for molidustat in patients with renal anemia undergoing dialysis

Nov. 4, 2020

dEF-3122 improves inflammation and fibrosis in liver and kidneys of NASH mice

Nov. 3, 2020

First-in-class LDHA inhibitor CHK-336 for treating primary hyperoxaluria

Nov. 3, 2020

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Oct. 28, 2020

J2H Biotech, Ahn-Gook Pharmaceutical describe new mirabegron prodrugs

Oct. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.